Long-Term Data Confirm Durability Of Medtronic’s DTM Back Pain Therapy
Executive Summary
A randomized trial demonstrated the superiority of Medtronic’s DTM spinal cord stimulation waveform over conventional spinal cord stimulation for treating back pain.
You may also be interested in...
Nevro And Medtronic Announce FDA Approval Of Spinal Cord Stimulation Label Expansions
The FDA approved a diabetic peripheral neuropathy indication for Medtronic’s Intellis and Vanta spinal cord stimulators a few days after expanding the indication for Senza Nevro’s spinal cord stimulation system to include non-surgical refractory back pain.
Medtronic Bounces Back During Quarter Four Of Financial Year 2021 As Procedure Volumes Normalize
Medtronic reported strong growth for the past quarter, with CEO Geoff Martha emphasizing the medtech giant’s efforts in M&A and R&D.
NANS 2020: Medtronic’s DTM Spinal Cord Stimulation Relieves Back Pain In Trial
Three-month results from a 94-patient randomized trial of Medtronic’s Intellis spinal cord stimulation system showed superior back-pain relief with the differential target multiplexed waveform compared to conventional spinal cord stimulation.